Should I buy Elevance Health (ELV) stock or is it too late?
⭐ The most reliable of them, either direction: Bernstein — 69% of its targets hit on this sector (70 calls tested). It aims for $488 (+15 %), call made on July 18, 2026, maturing on July 18, 2027 (88 d ago).
Firm-by-firm track record on Elevance Health
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 67 % | +12.4 % | 9 | $460 +8% |
| Deutsche Bank | 67 % | +11.7 % | 9 | $498 +17% |
| Morgan Stanley | 70 % | +10.8 % | 23 | $404 -5% |
| Jefferies | 70 % | +10.4 % | 10 | $391 -8% |
| Barclays | 65 % | +4.9 % | 20 | $469 +10% |
| Wells Fargo | 50 % | +3.2 % | 16 | $473 +11% |
| Truist Securities | 55 % | +2.5 % | 11 | $475 +12% |
| JP Morgan | 62 % | +1.0 % | 8 | $476 +12% |
✅ Reasons to believe
- 72% of analysts rate it a buy (Buy consensus, 18 ratings) — a sign of market conviction.
- Median price target $460, i.e. +8% from the current price ($425).
- Pays a dividend (1.6% yield), raised for 14 years — regular income on top of potential upside.
- Reasonable valuation (P/E ~19) relative to its sector.
⚠️ Reasons to hesitate
- Even the most reliable firm on ELV, Morgan Stanley (70% hit rate, 23 scored calls), only targets $404 (call made on June 4, 2026, maturing on June 4, 2027) (-5%) in its most recent call, and $352 (call made on December 18, 2025, maturing on December 18, 2026) (-17%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 18 ratings, 5 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on ELV
Median target $460 (+8%) · 18 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Elevance Health now?
We won't decide for you. The facts: 72% of analysts rate it a buy, median target $460 (+8%), and Morgan Stanley (most reliable on ELV, 70%) targets $404. Weigh that against valuation (P/E ~19). This is not personalized advice.
Is it too late to invest in Elevance Health?
Not according to analysts: the median target ($460) is still +8% above the current price ($425) (most reliable on ELV: Morgan Stanley, 70%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Elevance Health still worth investing in?
It depends on the gap between the price ($425) and its estimated value: analysts target $460 on median (+8%), with 72% buys (most reliable on ELV: Morgan Stanley, 70%). Cross-check with their real reliability on ELV and the cautions above. Information, not advice.
What's the main risk in buying ELV?
Even the most reliable firm on ELV, Morgan Stanley (70% hit rate, 23 scored calls), only targets $404 (call made on June 4, 2026, maturing on June 4, 2027) (-5%) in its most recent call, and $352 (call made on December 18, 2025, maturing on December 18, 2026) (-17%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Elevance Health profile (consensus, analyst reliability, price target, performance).